Ovarian cancer drug olaparib approved in Scotland as new treatment

A trial finds that Olaparib tablets can significantly slow down progression of the disease.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news

Related Links:

CONCLUSIONS: Secondary cytoreduction remains a viable treatment option for select patients for now, but this is entirely dependent on the highly anticipated overall survival results of DESKTOP III and SOC 1. PMID: 32649655 [PubMed - as supplied by publisher]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
Authors: O'Malley D PMID: 32649652 [PubMed - as supplied by publisher]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
Publication date: Available online 11 July 2020Source: Medical Journal Armed Forces IndiaAuthor(s): Nikita Naredi, Pankaj Talwar, Sandeep Karunakaran
Source: Medical Journal Armed Forces India - Category: General Medicine Source Type: research
Authors: Grandi G, Caroli M, Cortesi L, Toss A, Tazzioli G, Facchinetti F Abstract INTRODUCTION: Risk-reducing-salpingo-oophorectomy (RRSO) inevitably leads BRCA mutation carriers to premature menopause. AREAS COVERED: To evaluate the existing evidence for use of postmenopausal hormone therapy (HT) in BRCAmc, after RRSO or menopause occurring naturally, for both breast cancer (BC) survivors and those without BC. EXPERT OPINION: All BC survivors are excluded from any HT treatment: in other BRCAmc, before 51 years of age the benefits of HT overcome the risks after RRSO and/or premature ovarian insufficie...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
ConclusionPatients with cancer who need treatment can be treated by taking some measures. These measures include observing individual and collective protection principles in patients and health-care personnel, increasing patients ’ awareness particularly about self-care behavior, performing a COVID-19 test, and taking a chest X-ray, before the treatment starts
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
The original version of this article unfortunately contained a mistake. Complete figure captions are missing.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
AbstractMeigs ’ syndrome (MS), a rare complication of benign ovarian tumors, is easily misdiagnosed as ovarian cancer (OC). We retrospectively reviewed the clinical laboratory data of patients diagnosed with MS from 2009 to 2018. Serum carbohydrate antigen 125 and HE4 levels were higher in the MS group than in the ovarian thecoma-fibroma (OTF) and healthy control groups (allP
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
Authors: Zhao L, Li JF, Tong XJ Abstract OBJECTIVE: Recently, the role of long noncoding RNAs (lncRNAs) in tumor progression has attracted much attention worldwide. Numerous studies have identified lncRNA PROX1-AS1 as an oncogene in cancers. Therefore, the aim of this research was to explore the function of PROX1-AS1 in the development of ovarian cancer. PATIENTS AND METHODS: PROX1-AS1 expression in both ovarian cancer patients and normal subjects was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Subsequently, PROX1-AS1 shRNA was constructed and transfected in vitro. 3-(4,5-dimethylthi...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Abstract The idiopathic inflammatory myopathies, particularly dermatomyositis, are associated with an increased risk of cancer. Lung, ovarian, breast, colon, prostate, and cervical cancers, and hematologic malignancies, are among the most common associated cancers. Risk stratification for cancer in patients with myositis is based on clinical risk factors/red flags, myositis clinical subtypes, and myositis-specific autoantibodies. Clinical risk factors include older age at disease onset, male gender, dysphagia, acute onset/refractory myositis, cutaneous ulceration, necrosis/vasculitis, and elevated inflammatory mar...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Rheum Dis Clin North Am Source Type: research
Abstract Systemic lupus erythematosus is associated with a small overall increased cancer risk compared with the general population. This risk includes a 4-fold increased risk of non-Hodgkin lymphoma, but a decreased risk of other cancers (such as breast cancer). The pathophysiology underlying the increased risk of hematologic cancer is not fully understood, but many potential mechanisms have been proposed, including dysfunction of the tumor necrosis factor and other pathways. A decreased risk of breast, ovarian, and endometrial cancer might be driven by hormonal factors or lupus-related antibodies, but these link...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Rheum Dis Clin North Am Source Type: research
More News: Cancer | Cancer & Oncology | Health | Ovarian Cancer | Ovaries | Scotland Health